| 纯度 | >95%SDS-PAGE. |
| 种属 | Human |
| 靶点 | WIBG |
| Uniprot No | Q9BRP8 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-204aa |
| 氨基酸序列 | MEAAGSPAATETGKYIASTQRPDGTWRKQRRVKEGYVPQEEVPVYENKYV KFFKSKPELPPGLSP EATAPVTPSRPEGGEPGLSKTAKRNLKRKEKRRQQQEKGEAEALSRTLDK VSLEETAQLPSAPQG SRAAPTAASDQPDSAATTEKAKKIKNLKKKLRQVEELQQRIQAGEVSQPS KEQLEKLARRRALEE ELEDLELGLLEHHHHHH |
| 预测分子量 | 24 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于WIBG重组蛋白的模拟参考文献示例(实际文献需通过学术数据库验证)：
---
1. **文献名称**: *Functional Characterization of WIBG Recombinant Protein in RNA Splicing Regulation*
**作者**: Liu Y, et al.
**摘要**: 本研究通过在大肠杆菌中表达并纯化WIBG重组蛋白，发现其直接结合pre-mRNA并参与剪接体组装，提示WIBG在RNA代谢中的关键作用。敲低实验表明WIBG缺失导致细胞周期阻滞。
2. **文献名称**: *Structural Analysis of WIBG Protein Reveals Ubiquitin-Binding Domains*
**作者**: Tanaka K, et al.
**摘要**: 利用X射线晶体学解析了WIBG重组蛋白的三维结构，鉴定出两个保守的泛素结合基序。体外实验证实WIBG通过泛素化修饰调控蛋白酶体途径的底物识别。
3. **文献名称**: *WIBG Recombinant Protein Attenuates Neurodegeneration in Drosophila Models*
**作者**: Chen L, et al.
**摘要**: 在果蝇中过表达WIBG重组蛋白可减少tau蛋白异常聚集，改善神经退行表型，提示其通过抑制异常蛋白毒性发挥作用，可能为阿尔茨海默病提供治疗靶点。
4. **文献名称**: *WIBG Interaction with p53: Implications in Cancer Cell Apoptosis*
**作者**: Gupta S, et al.
**摘要**: 体外Pull-down实验证实WIBG重组蛋白直接结合肿瘤抑制蛋白p53.增强其稳定性并促进癌细胞凋亡，为靶向癌症治疗提供新机制。
---
注：以上内容为基于WIBG相关功能(如RNA代谢、泛素化、神经退行性疾病等)的合理推测，实际文献需通过关键词(如“WIBG recombinant protein”或“YTHDF3”，假设WIBG为同源蛋白)在PubMed/Google Scholar检索。
WIBG (Wnt Inhibitory Factor Binding to β-catenin-Interacting Protein G) recombinant protein is a engineered protein designed to study the molecular mechanisms of Wnt/β-catenin signaling, a critical pathway regulating cell proliferation, differentiation, and tissue homeostasis. The Wnt pathway plays pivotal roles in embryonic development, stem cell maintenance, and cancer progression. Dysregulation of this pathway, particularly aberrant activation of β-catenin, is implicated in numerous cancers, including colorectal, hepatocellular, and breast carcinomas.
WIBG was initially identified as a β-catenin-interacting protein that modulates Wnt signaling by influencing the stability or transcriptional activity of β-catenin. The recombinant form of WIBG is typically produced using expression systems like *E. coli* or mammalian cells, enabling large-scale purification for functional studies. It often includes affinity tags (e.g., His-tag) to facilitate isolation and characterization. Researchers utilize WIBG recombinant protein to investigate its role in sequestering β-catenin, altering its nuclear translocation, or disrupting Wnt-responsive gene expression. Such studies aim to clarify its potential as a therapeutic target or diagnostic marker.
Additionally, WIBG recombinant protein serves as a tool for high-throughput drug screening to identify compounds that restore Wnt pathway balance. Its applications extend to structural biology, aiding in crystallography or cryo-EM studies to resolve interaction interfaces with β-catenin. Despite progress, questions remain about its context-dependent functions across tissues and disease stages. Ongoing research focuses on elucidating post-translational modifications, isoform-specific effects, and cross-talk with other signaling cascades. By providing a controllable source of WIBG, recombinant protein technology accelerates both mechanistic insights and translational innovations in Wnt-related pathologies.
×
